Dataset Information

?-Arrestin 2 dependence of ? opioid receptor agonists is correlated with alcohol intake.

ABSTRACT:

Background and purpose

? Opioid receptor agonists are being developed as potential treatments for depression and alcohol use disorders. This is particularly interesting as depression is frequently co-morbid with alcohol use disorders. Yet we have previously shown that ? receptor agonists range widely in their ability to modulate alcohol intake; certain ? receptor agonists actually increase alcohol consumption in mice. We propose that variations in ?-arrestin 2 recruitment contribute to the differential behavioural profile of ? receptor agonists.

Experimental approach

We used three diarylmethylpiperazine-based non-peptidic ? receptor selective agonists (SNC80, SNC162 and ARM390) and three structurally diverse ? receptor agonists (TAN-67, KNT127 and NIH11082). We tested these agonists in cAMP and ?-arrestin 2 recruitment assays and a behavioural assay of alcohol intake in male C57BL/6 mice. We used ?-arrestin 2 knockout mice and a model of depression-like behaviour to further study the role of ?-arrestin 2 in ? receptor pharmacology.

Key results

All six tested ? receptor agonists were full agonists in the cAMP assay but displayed distinct ?-arrestin 2 recruitment efficacy. The efficacy of ? receptor agonists to recruit ?-arrestin 2 positively correlated with their ability to increase alcohol intake (P < 0.01). The effects of the very efficacious recruiter SNC80 on alcohol intake, alcohol place preference and depression-like behaviour were ?-arrestin 2-dependent.

Conclusions and implications

Our finding that ? receptor agonists that strongly recruit ?-arrestin 2 can increase alcohol intake carries important ramifications for drug development of ? receptor agonists for treatment of alcohol use disorders and depressive disorders.

SUBMITTER: Chiang T

PROVIDER: S-EPMC4940619 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

β-Arrestin 2 dependence of δ opioid receptor agonists is correlated with alcohol intake.

Chiang T T Sansuk K K van Rijn R M RM

British journal of pharmacology 20160101 2

<h4>Background and purpose</h4>δ Opioid receptor agonists are being developed as potential treatments for depression and alcohol use disorders. This is particularly interesting as depression is frequently co-morbid with alcohol use disorders. Yet we have previously shown that δ receptor agonists range widely in their ability to modulate alcohol intake; certain δ receptor agonists actually increase alcohol consumption in mice. We propose that variations in β-arrestin 2 recruitment contribute to t ...[more]

PMID: 26507558

Similar Datasets

Project description:Alcohol use disorder (AUD) is a chronic relapsing condition characterized by compulsive alcohol-seeking behaviors, with serious detrimental health consequences. Despite high prevalence and societal burden, available approved medications to treat AUD are limited in number and efficacy, highlighting a critical need for more and novel pharmacotherapies. Glucagon-like peptide-1 (GLP-1) is a gut hormone and neuropeptide involved in the regulation of food intake and glucose metabolism via GLP-1 receptors (GLP-1Rs). GLP-1 analogs are approved for clinical use for diabetes and obesity. Recently, the GLP-1 system has been shown to play a role in the neurobiology of addictive behaviors, including alcohol seeking and consumption. Here we investigated the effects of different pharmacological manipulations of the GLP-1 system on escalated alcohol intake and preference in male Wistar rats exposed to intermittent access 2-bottle choice of 10% ethanol or water. Administration of AR231453 and APD668, two different agonists of G-protein receptor 119, whose activation increases GLP-1 release from intestinal L-cells, did not affect voluntary ethanol intake. By contrast, injections of either liraglutide or semaglutide, two long-acting GLP-1 analogs, potently decreased ethanol intake. These effects, however, were transient, lasting no longer than 48 h. Semaglutide, but not liraglutide, also reduced ethanol preference on the day of injection. As expected, both analogs induced a reduction in body weight. Co-administration of exendin 9-39, a GLP-1R antagonist, did not prevent liraglutide- or semaglutide-induced effects in this study. Injection of exendin 9-39 alone, or blockade of dipeptidyl peptidase-4, an enzyme responsible for GLP-1 degradation, via injection of sitagliptin, did not affect ethanol intake or preference. Our findings suggest that among medications targeting the GLP-1 system, GLP-1 analogs may represent novel and promising pharmacological tools for AUD treatment.